Paragonimiasis Misdiagnosed as Pulmonary Tuberculosis: A Case Report
diffuse pneumonia :: Article Creator
Featured Post
Pulmonary nocardiosis in immunocompetent patients: can COPD be the only risk factor?
Tool Identifies Degree Of 1-year Mortality Risk In Patients With Chronic Lung Disease, PH
August 26, 2025
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.Com.Back to Healio
Key takeaways:A risk assessment tool including five factors identified whether patients with chronic lung disease and pulmonary hypertension face a high, intermediate or low risk for 1-year mortality, according to study results.
These findings were published in BMC Pulmonary Medicine.
"For frontline clinicians, the score offers several practical benefits: improved prognostication at the point of diagnosis; a framework to guide decisions regarding referral for lung transplantation, palliative care discussions or therapeutic escalation; and enhanced clarity in shared decision-making with patients and caregivers," Mario Naranjo-Tovar, MD, MHS, assistant professor of clinical thoracic medicine and surgery at the Lewis Katz School of Medicine at Temple University, told Healio.
"Because the score relies exclusively on data routinely collected in clinical practice, it is both feasible and scalable for real-world implementation," Naranjo-Tovar said.
In a retrospective cohort study, Naranjo-Tovar and colleagues evaluated 793 patients (mean age, 63.3 years; 50.8% men; 49.9% non-Hispanic white) with chronic lung disease and pulmonary hypertension (PH) to determine predictors of 1-year mortality from time of PH diagnosis, create a risk assessment tool using this information and validate it.
"Patients with chronic lung diseases — like pulmonary fibrosis or COPD — often go on to develop PH, a condition that dramatically worsens survival," Naranjo-Tovar told Healio. "However, clinicians have lacked a validated, disease-specific tool to predict mortality in this high-risk group.
"Existing risk scores are designed for pulmonary arterial hypertension and don't adequately account for the unique pathophysiology seen in patients whose PH arises from underlying lung disease," he added.
The most common underlying lung disease in this population was COPD (41.6%), followed by pulmonary fibrosis without emphysema (31.7%), combined pulmonary fibrosis and emphysema (13.2%), advanced pulmonary sarcoidosis (8.8%) and non-fibrotic interstitial lung disease (4.7%).
Using multivariable Cox regression, researchers found five factors that significantly raised the risk for 1-year mortality and were deemed predictors:
"Notably, mean pulmonary artery pressure — a cornerstone metric for diagnosing PH — did not emerge as an independent predictor of 1-year mortality," Naranjo-Tovar told Healio. "This suggests that traditional hemodynamic severity may be less prognostically relevant in chronic lung disease-associated PH than previously assumed.
"These insights reinforced the notion that functional capacity (eg, 6-minute walk distance) and biomarkers of cardiac strain (eg, BNP) may offer superior predictive value over isolated hemodynamic metrics in this population," he continued.
The study reported that each predictor was given a point value based on its hazard ratio, meaning that pulmonary fibrosis without emphysema had the highest point value (4 points), age older than 65 and BNP greater than 200 pg/dL had the second highest point value (each 3 points) and 6MWD less than 150 m and PVR greater than 5 WU had the lowest point value (each 2 points).
Researchers outlined that a total score of 0 to 3 signaled low risk, a score of 4 to 10 signaled intermediate risk and a score of 11 to 14 signaled high risk. Using these ranges in the 407 patients with full data to calculate a risk score, 155 had low risk, 212 had intermediate risk and 40 had high risk.
Aligning with their calculated PVD-B65 tool risk score, the high-risk group had the highest proportion of patients who died by 1 year at 17.5%, according to the study. Following suit, the intermediate-risk group had the second highest proportion (9.4%) and the low-risk group had the lowest proportion (3.9%).
Researchers also found that the risk for 1-year mortality was significantly elevated among those with high vs. Low risk (HR = 6.2; 95% CI, 2.08-18.48) and those with intermediate vs. Low risk (HR = 2.59; 95% CI, 1.04-4.65) in Cox regression analysis.
Additionally, 1-year survival probability significantly differed between those with high vs. Intermediate risk and those with intermediate vs. Low risk in Kaplan-Meier survival analysis, according to the study.
Lastly, researchers reported that the PVD-B65 risk score calculator achieved internal validation in Cox regression with bootstrapping, noting that the findings were comparable to those observed above in the original Cox regression analysis.
"The development of the PVD-B65 score represents a significant advancement in risk stratification for chronic lung disease-PH patients," Naranjo-Tovar told Healio. "By integrating five binary clinical variables, the model provides an intuitive, evidence-based method for estimating 1-year mortality risk."
Moving forward, Naranjo-Tovar said external validation is needed.
"Future investigations will focus on external validation across diverse patient cohorts and health care systems to assess the model's generalizability," Naranjo-Tovar told Healio.
"The PVD-B65 score fills a longstanding gap in pulmonary vascular medicine: a validated, lung disease-specific tool to predict 1-year mortality in patients with PH," he said. "It's clinically accessible, prognostically robust and offers a new lens through which clinicians can individualize care for a complex and vulnerable population."
For more information:Mario Naranjo-Tovar, MD, MHS, can be reached at mario.Naranjo-tovar@tuhs.Temple.Edu.
Perspective Back to Top PH in the context of chronic lung disease remains a formidable clinical challenge, often portending poor outcomes and limited therapeutic clarity. In this study, Gayen et al introduce the PVD-B65 risk score — a novel, internally validated tool designed to predict 1-year mortality in patients with PH in the setting of chronic lung disease. The retrospective cohort included 793 patients diagnosed with severe PH diagnosed via right heart catheterization (mPAP > 35 mmHg or mPAP 25 mmHg with reduced cardiac index in accordance with the 2015 guidelines, or PV > 5 WU in accordance with 2022 guidelines) between 2011 and 2023. Underlying lung diseases included COPD (42%), pulmonary fibrosis without emphysema (32%), CPFE (13%), sarcoidosis (9%) and non-fibrotic ILD (5%). The score integrates five variables: pulmonary fibrosis without emphysema, pulmonary vascular resistance (PVR) greater than 5 WU, 6MWD less than 150 m, BNP greater than 200 pg/mL and age greater than 65 years. The score stratifies patients into low, intermediate and high-risk categories with statistically significant survival differences. Clinically, this tool has the potential to address an important gap. Existing risk models, largely derived from PAH cohorts, fail to account for the heterogeneity and complexity of PH in chronic lung disease. Further, the components of the risk score (PVR, 6MWD, BNP, type of chronic lung disease) are already widely used in clinical practice, increasing its appeal for "real world" applications. When a patient scores in the intermediate or high-risk categories, for example, clinicians may be prompted to augment therapy (when feasible) or refer for consideration of lung transplant, if appropriate. External validation of the tool is certainly warranted and will likely be quite informative. Going forward, risk stratification tools tailored toward specific types of chronic lung disease — which are both clinically and physiologically heterogeneous — would be invaluable, particularly as treatment options continue to evolve. Nonetheless, the PVD-B65 risk score's simplicity and applicability make it a promising candidate for integration into routine practice. Kathryn T. Del Valle, MD Assistant Program Director and Assistant Professor of Medicine, Mayo Clinic Pulmonary Hypertension Fellowship ProgramDisclosures: Del Valle reports no relevant financial disclosures.
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.Com.Back to Healio
Chronic Obstructive Pulmonary Disease - Nature
Vestbo, J. Et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am. J. Respir. Crit. Care Med. 187, 347–365 (2013). This strategy document is often regarded as the COPD standard and is the basis for most national guidelines.
Lange, P. Et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N. Engl. J. Med. 373, 111–122 (2015).
Lozano, R. Et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic for the Global Burden of Disease Study 2010. Lancet 380, 2095–2128 (2013).
Burney, P. G., Patel, J., Newson, R., Minelli, C. & Naghavi, M. Global and regional trends in COPD mortality, 1990–2010. Eur. Respir. J. 45, 1239–1247 (2015). This paper demonstrates that the cross-sectional association found between mortality from chronic lung disease and gross national income is also reflected in an association between the change in mortality from chronic lung disease and the change in gross national income. The association is less prone to confounding by other large differences between regions.
Gershon, A. S., Warner, L., Cascagnette, P., Victor, J. C. & To, T. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet 378, 991–996 (2011).
Yawn, B. Et al. Prevalence of COPD among symptomatic patients in a primary care setting. Curr. Med. Res. Opin. 25, 2671–2677 (2009).
Buist, A. S. Et al. International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet 370, 741–750 (2007).
Menezes, A. M. Et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur. Respir. J. 30, 1180–1185 (2007).
Hooper, R. Et al. Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. Eur. Respir. J. 39, 1343–1353 (2012).
Blanc, P. D. Et al. Further exploration of the links between occupational exposure and chronic obstructive pulmonary disease. J. Occup. Environ. Med. 51, 804–810 (2009).
Chinn, S., Florey, C. D., Baldwin, I. G. & Gorgol, M. The relation of mortality in England and Wales1969–1973 to measurements of air pollution. J. Epidemiol. Commun. Health 35, 174–179 (1981).
Salvi, S. & Barnes, P. Chronic obstructive pulmonary disease in non-smokers. Lancet 374, 733–743 (2009).
Burnett, R. T. Et al. An integrated risk function for estimating the global burden of disease attributable to ambient fine particulate patter exposure. Environ. Health Persp. 122, 397–403 (2014).
Romieu, I. Et al. Improved biomass stove intervention in rural Mexico: impact on the respiratory health of women. Am. J. Respir. Crit. Care Med. 180, 649–656 (2009).
Zhou, Y. Et al. Lung function and incidence of chronic obstructive pulmonary disease after improved cooking fuels and kitchen ventilation: a 9-year prospective cohort study. PLoS Med. 11, e1001621 (2014).
Smith, M. Et al. Prevalence and correlates of airflow obstruction in 317,000 never-smokers in China. Eur. Respir. J. 44, 66–77 (2014).
Burney, P. Et al. Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty — a BOLD analysis. Thorax 69, 465–473 (2014). This paper shows that the prevalence of airflow obstruction is strongly associated with the prevalence of smoking, as judged by the mean pack years smoked, and that the prevalence of a low FVC is strongly associated with poverty. The prevalence of a low FVC is most closely associated with mortality rates.
Office of Population Censuses and Surveys. Occupational Mortality: The Registrar General's Decennial Supplement for Great Britain, 1979–80, 1982–1983 (Her Majesty's Stationery Office, 1986).
Marks, G. & Burney, P. In The Health of Adult Britain 1841–1991 Vol. 2 (eds Charlton, J. & Murphy, M. ) 93–113 (Her Majesty's Stationery Office, 1997).
Barker, D. J. & Osmond, C. Childhood respiratory infection and adult chronic bronchitis in England and Wales. BMJ (Clin. Res. Ed.) 293, 1271–1275 (1986). This is an early paper from Barker and Osmond showing that mortality rates from chronic airway disease later in adult life is associated with mortality in the same areas from bronchitis and pneumonia among children half a century earlier. This association was not true for lung cancer rates, and Barker and Osmond suggest that this is evidence that the environment encountered during early life has an important impact on subsequent lung health.
Gnatiuc, L. Et al. Gaps in using bronchodilators, inhaled corticosteroids and influenza vaccine among 23 high- and low-income sites. Int. J. Tuberc. Lung Dis. 19, 21–30 (2015).
Ingebrigtsen, T. Et al. Genetic influences on chronic obstructive pulmonary disease — a twin study. Respir. Med. 104, 1890–1895 (2010).
McCloskey, S. C. Et al. Siblings of patients with severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction. Am. J. Respir. Crit. Care Med. 164, 1419–1424 (2001).
Silverman, E. K. Et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease: risk to relatives for airflow obstruction and chronic bronchitis. Am. J. Respir. Crit. Care Med. 157, 1770–1778 (1998).
Zhou, J. J. Et al. Heritability of chronic obstructive pulmonary disease and related phenotypes in smokers. Am. J. Respir. Crit. Care Med. 188, 941–947 (2013).
Silverman, E. K. & Sandhaus, R. A. Clinical practice. Alpha1-antitrypsin deficiency. N. Engl. J. Med. 360, 2749–2757 (2009).
Sorheim, I. C. Et al. α1-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest 138, 1125–1132 (2010).
Molloy, K. Et al. Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am. J. Respir. Crit. Care Med. 189, 419–427 (2014).
Rodriguez-Revenga, L. Et al. A novel elastin gene mutation resulting in an autosomal dominant form of cutis laxa. Arch. Dermatol. 140, 1135–1139 (2004).
Kelleher, C. M. Et al. A functional mutation in the terminal exon of elastin in severe, early-onset chronic obstructive pulmonary disease. Am. J. Respir. Cell. Mol. Biol. 33, 355–362 (2005).
Wain, L. V. Et al. Whole exome re-sequencing implicates CCDC38 and cilia structure and function in resistance to smoking related airflow obstruction. PLoS Genet. 10, e1004314 (2014).
Castaldi, P. J. Et al. The COPD genetic association compendium: a comprehensive online database of COPD genetic associations. Hum. Mol. Genet. 19, 526–534 (2010).
Smolonska, J., Wijmenga, C., Postma, D. S. & Boezen, H. M. Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years' research. Am. J. Respir. Crit. Care Med. 180, 618–631 (2009).
Cho, M. H. Et al. Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. Lancet Respir. Med. 2, 214–225 (2014). This collaborative genome-wide association study identifies four genetic loci for moderate-to-severe COPD and two additional loci for severe COPD. Although highly significant, these genetic loci are of modest effect size.
Hancock, D. B. Et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat. Genet. 42, 45–52 (2010).
Repapi, E. Et al. Genome-wide association study identifies five loci associated with lung function. Nat. Genet. 42, 36–44 (2010).
Soler Artigas, M. Et al. Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat. Genet. 43, 1082–1090 (2011).
Castaldi, P. J. Et al. Genome-wide association identifies regulatory loci associated with distinct local histogram emphysema patterns. Am. J. Respir. Crit. Care Med. 190, 399–409 (2014).
Siedlinski, M. Et al. Genome-wide association study of smoking behaviours in patients with COPD. Thorax 66, 894–902 (2011).
Thorgeirsson, T. E. Et al. Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior. Nat. Genet. 42, 448–453 (2010).
Amos, C. I. Et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 40, 616–622 (2008).
Thorgeirsson, T. E. Et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452, 638–642 (2008).
DeMeo, D. L. Et al. Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. Am. J. Hum. Genet. 85, 493–502 (2009).
Siedlinski, M. Et al. Dissecting direct and indirect genetic effects on chronic obstructive pulmonary disease (COPD) susceptibility. Hum. Genet. 132, 431–441 (2013).
Zhou, X. Et al. Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIP. Hum. Mol. Genet. 21, 1325–1335 (2012). With a COPD genome-wide association study region, chromatin interaction studies followed by functional analyses identified a likely functional genetic variant. This is one of the first examples of functional variant identification with a complex disease genome-wide association study locus.
Lao, T. Et al. Haploinsufficiency of Hedgehog interacting protein causes increased emphysema induced by cigarette smoke through network rewiring. Genome Med. 7, 12 (2015).
Castaldi, P. J. Et al. Genetic control of gene expression at novel and established chronic obstructive pulmonary disease loci. Hum. Mol. Genet. 24, 1200–1210 (2015).
Qiu, W. Et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. Am. J. Respir. Crit. Care Med. 185, 373–381 (2012).
Hogg, J. C. & Timens, W. The pathology of chronic obstructive pulmonary disease. Annu. Rev. Pathol. 4, 435–459 (2009).
McDonough, J. E. Et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N. Engl. J. Med. 365, 1567–1575 (2011).
Galban, C. J. Et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat. Med. 18, 1711–1715 (2012).
Peinado, V. I., Pizarro, S. & Barbera, J. A. Pulmonary vascular involvement in COPD. Chest 134, 808–814 (2008).
Seeger, W. Et al. Pulmonary hypertension in chronic lung diseases. J. Am. Coll. Cardiol. 62, D109–D116 (2013).
Barnes, P. J. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin. Chest Med. 35, 71–86 (2014).
Brusselle, G. G., Joos, G. F. & Bracke, K. R. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 378, 1015–1026 (2011).
Barnes, P. J. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Immunol. Rev. 8, 183–192 (2008).
McAleer, J. P. & Kolls, J. K. Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol. Rev. 260, 129–144 (2014).
Barrecheguren, M., Esquinas, C. & Miravitlles, M. The asthma–chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges. Curr. Opin. Pulm. Med. 21, 74–79 (2015).
Barnes, P. J. Cytokine networks in asthma and chronic obstructive pulmonary disease. J. Clin. Invest. 118, 3546–3556 (2008).
Di Stefano, A. Et al. Increased expression of NF-κB in bronchial biopsies from smokers and patients with COPD. Eur. Respir. J. 20, 556–563 (2002).
Renda, T. Et al. Increased activation of p38 MAPK in COPD. Eur. Respir. J. 31, 62–69 (2008).
Ito, K. Et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 352, 1967–1976 (2005). This study demonstrates that COPD lungs have decreased expression and activity of the nuclear enzyme HD2, which is required for corticosteroids to switch off inflammatory genes. This result explains the amplified inflammation and corticosteroid resistance in patients with COPD.
Taylor, A. E. Et al. Defective macrophage phagocytosis of bacteria in COPD. Eur. Respir. J. 35, 1039–1047 (2010).
Donnelly, L. E. & Barnes, P. J. Defective phagocytosis in airways disease. Chest 141, 1055–1062 (2012).
Singh, R. Et al. Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease. Respir. Res. 15, 114 (2014).
Mukaro, V. R. & Hodge, S. Airway clearance of apoptotic cells in COPD. Curr. Drug Targets 12, 460–468 (2011).
Kirkham, P. A. Et al. Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of COPD. Am. J. Respir. Crit. Care Med. 184, 796–802 (2011).
Barnes, P. J. Chronic obstructive pulmonary disease: effects beyond the lungs.PLoS Med. 7, e1000220 (2010).
Agusti, A. Et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 7, e37483 (2012).
Ito, K. & Barnes, P. J. COPD as a disease of accelerated lung aging. Chest 135, 173–180 (2009).
Mercado, N., Ito, K. & Barnes, P. J. Accelerated ageing in chronic obstructive pulmonary disease: new concepts. Thorax 70, 482–489 (2015). A review of the accelerated ageing process in COPD and the molecular mechanisms involved; this article also identifies novel targets for future therapies.
Paschalaki, K. E. Et al. Dysfunction of endothelial progenitor cells from smokers and COPD patients due to increased DNA damage and senescence. Stem Cells 31, 2813–2826 (2013).
Barnes, P. J. Mechanisms of development of multimorbidity in the elderly. Eur. Respir. J. 45, 790–806 (2015).
Madeo, F., Zimmermann, A., Maiuri, M. C. & Kroemer, G. Essential role for autophagy in life span extension. J. Clin. Invest. 125, 85–93 (2015).
Mizumura, K., Cloonan, S. M., Haspel, J. A. & Choi, A. M. The emerging importance of autophagy in pulmonary diseases. Chest 142, 1289–1299 (2012).
Kirkham, P. A. & Barnes, P. J. Oxidative stress in COPD. Chest 144, 266–273 (2013).
Caramori, G. Et al. Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer. Thorax 66, 521–527 (2011).
Barnes, P. J. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 131, 636–645 (2013).
Nakamaru, Y. Et al. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J. 23, 2810–2819 (2009).
Malhotra, D. Et al. Expression of concern: decline in NRF2 regulated antioxidants in COPD lungs due to loss of its positive regulator DJ-1. Am. J. Respir. Crit. Care Med. 178, 592–604 (2008).
Mercado, N. Et al. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem. Biophys. Res. Commun. 406, 292–298 (2011).
Hara, H. Et al. Mitochondrial fragmentation in cigarette smoke-induced bronchial epithelial cell senescence. Am. J. Physiol. Lung Cell. Mol. Physiol. 305, L737–L746 (2013).
Mizumura, K. Et al. Mitophagy-dependent necroptosis contributes to the pathogenesis of COPD. J. Clin. Invest. 124, 3987–4003 (2014).
Guenette, J. A., Webb, K. A. & O'Donnell, D. E. Does dynamic hyperinflation contribute to dyspnoea during exercise in patients with COPD? Eur. Respir. J. 40, 322–329 (2012).
Wedzicha, J. A. & Seemungal, T. A. COPD exacerbations: defining their cause and prevention. Lancet 370, 786–796 (2007). This paper provides an excellent insight into the nature of exacerbations of COPD, their importance, clinical consequences and prevention of their occurrence.
Seemungal, T. Et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164, 1618–1623 (2001).
George, S. N. Et al. Human rhinovirus infection during naturally occurring COPD exacerbations. Eur. Respir. J. 44, 87–96 (2014).
Peacock, J. L. Et al. Outdoor air pollution and respiratory health in patients with COPD. Thorax 66, 591–596 (2011).
Seemungal, T. A. Et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 157, 1418–1422 (1998).
Hurst, J. R. Et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 363, 1128–1138 (2010).
Wedzicha, J. A., Brill, S. E., Allinson, J. P. & Donaldson, G. C. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 11, 181 (2013).
Celli, B. R. & MacNee, W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 23, 932–946 (2004).
Barr, R. G. Et al. Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. Am. J. Med. 118, 1415 (2005).
Cote, C. G. & Chapman, K. R. Diagnosis and treatment considerations for women with COPD. Int. J. Clin. Pract. 63, 486–493 (2009).
Lundback, B. Et al. Not 15 but 50% of smokers develop COPD? — Report from the Obstructive Lung Disease in Northern Sweden studies. Respir. Med. 97, 115–122 (2003).
Sood, A. Et al. Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers. Am. J. Respir. Crit. Care Med. 182, 1098–1104 (2010).
Celli, B. R., Halbert, R. J., Nordyke, R. J. & Schau, B. Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. Am. J. Med. 118, 1364–1372 (2005).
Stern, D. A., Morgan, W. J., Wright, A. L., Guerra, S. & Martinez, F. D. Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. Lancet 370, 758–764 (2007).
Sanchez-Salcedo, P. Et al. Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. Eur. Respir. J. 44, 324–331 (2014).
Erb-Downward, J. R. Et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS ONE 6, e16384 (2011).
Burgel, P. R. Et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur. Respir. J. 36, 531–539 (2012).
Garcia-Aymerich, J. Et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 66, 430–437 (2011).
Rennard, S. Et al. Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann. Am. Thorac. Soc. 12, 303–312 (2014).
Miller, M. R. Et al. Standardisation of spirometry. Eur. Respir. J. 26, 319–338 (2005).
Swanney, M. P. Et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 63, 1046–1051 (2008).
Hankinson, J. L., Odencrantz, J. R. & Fedan, K. B. Spirometric reference values from a sample of the general U. S. Population. Am. J. Respir. Crit. Care Med. 159, 179–187 (1999).
Celli, B. R. Et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 350, 1005–1012 (2004). This work provides the first objective evidence of the importance of non-pulmonary involvement in patients with COPD. In addition, it prospectively validates the measurement of a multidimensional index to prognosticate outcome in patients with COPD.
Watz, H. Et al. An official European Respiratory Society statement on physical activity in COPD. Eur. Respir. J. 44, 1521–1537 (2014).
Nici, L., ZuWallack, R. & American Thoracic Society Subcommittee on Integrated Care of the COPD Patient. An official American Thoracic Society workshop report: the Integrated Care of the COPD Patient. Proc. Am. Thorac. Soc. 9, 9–18 (2012).
Maltais, F. Et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 189, e15–e62 (2014).
Puhan, M. A. Et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 374, 704–711 (2009).
Jones, R. C. Et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE index. Am. J. Respir. Crit. Care Med. 180, 1189–1195 (2009).
Marin, J. M. Et al. Multicomponent indices to predict survival in COPD: the COCOMICS study. Eur. Respir. J. 42, 323–332 (2013).
Divo, M. Et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 186, 155–161 (2012).
Gietema, H. A. Et al. Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort. Acad. Radiol. 18, 661–671 (2011).
de Torres, J. P. Et al. Lung cancer in patients with chronic obstructive pulmonary disease — incidence and predicting factors. Am. J. Respir. Crit. Care Med. 184, 913–919 (2011).
Vestbo, J. Et al. Changes in forced expiratory volume in 1 second over time in COPD. N. Engl. J. Med. 365, 1184–1192 (2011).
Popular Posts
“Teaching a pandemic in real time, part 2 . Princeton professors share how they incorporate the study - Princeton University” plus 1 more
“Teaching a pandemic in real time, part 2 . Princeton professors share how they incorporate the study - Princeton University” plus 1 more Teaching a pandemic in real time, part 2 . Princeton professors share how they incorporate the study - Princeton University Posted: 28 Jun 2021 09:09 AM PDT The pandemic changed not only how Princeton University students were learning after the transition to remote teaching in March 2020, but also what they were learning — especially as the impact of COVID-19 opened new lines of humanistic and scientific inquiry across fields of study. In this second installment about teaching the pandemic in real time ( read part one ), Princeton professors share how they incorporated the coronavirus and the pandemic's effects into their course material during the spring 2021 semester. The Art & Archaeology of Plague Janet Kay, lecturer in art and archaeology Is this a new course or an existing course...
Community-Acquired Pneumonia |Clinical Guidance
quest diagnostics tb test :: Article Creator GRAIL And Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through The Quest Diagnostics Test Ordering System - Yahoo Finance GRAIL's Galleri Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience MENLO PARK, Calif. And SECAUCUS, N.J., Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the initial phase of a program to improve provider access to GRAIL's Galleri® multi-cancer early detection (MCED) test. Providers can now order the Galleri test directly from GRAIL through the Quest Diagnostics connectivity system. The Quest Diagnostics connectivity system enab...
“John Singleton's family urges black men to get their blood pressure checked - NBC News” plus 3 more
“John Singleton's family urges black men to get their blood pressure checked - NBC News” plus 3 more John Singleton's family urges black men to get their blood pressure checked - NBC News Minneapolis Police Officer Convicted of Murder in Shooting of Australian Woman - The New York Times For Black Drivers, Traffic Stops Can Be a Matter of Life or Death. Can the 'Not Reaching' Pouch Make Them Safer? - The Root ‘Avengers: Endgame’ Writers Break Silence on Killing Off Major MCU Superheroes - IndieWire John Singleton's family urges black men to get their blood pressure checked - NBC News Posted: 30 Apr 2019 11:53 AM PDT Breaking News Emails Get breaking news alerts and special reports. The news and stories that matter, delivered weekday mornings. SUBSCRIBE April 30, 2019, 6:53 PM UTC By Shamard Charles, M.D. Filmmaker John Singl...
Comments
Post a Comment